Scarica l'app Stockscreener
0.4867
0.88%
-0.0043
Dopo l'orario di chiusura:
.49
0.0033
+0.68%
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Yahoo Finance
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Investors Purchase Large Volume of Acurx Pharmaceuticals Call Options (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals Raises Fresh $2.67M Capital: New Antibiotic Development Gets Major Funding Boost - Stock Titan
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ - Yahoo Finance
Acurx Pharmaceuticals Inc (ACXP) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Crude Oil Rises Sharply; Jabil Earnings Top Views - Benzinga
US Stocks Lower; Retail Sales Decline In May - Benzinga
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside - FinancialContent
Acurx Pharmaceuticals Soars as Breakthrough Antibiotic Data Hits the Headlines - RagingBull
Banco Santander S.A. ADR Inc. (SAN) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Why Is Acurx Pharmaceuticals Stock (ACXP) Up 250% Today? - TipRanks
Breakthrough: New Antibiotic Achieves 94% Cure Rate Against C. Difficile, Outperforms Standard Treatment - Stock Titan
(PDF) A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens - researchgate.net
Mirum Pharmaceuticals Expands Team with 10 New Hires, Grants $5.7M Stock Options Package - Stock Titan
TJX Maintains Strong Dividend Program: Top Retail Chain Announces $0.425 Per Share Payout - Stock Titan
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - Akron Beacon Journal
Acurx announces presentation of results for DNA pol IIIC inhibitors - TipRanks
Acurx Pharmaceuticals Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA pol IIIC Inhibitors - marketscreener.com
Acurx (ACXP) Advances Antibiotic Candidate for C. difficile Treatment | ACXP Stock News - GuruFocus
Warner Bros. Discovery to split into two companies, dividing cable and streaming services - WFMZ.com
Breakthrough: New Antibiotic Class Shows Promise Against Drug-Resistant C. DifficilePhase 3 Ready - Stock Titan
Clostridium Difficile Infections Pipeline 2025: MOA and ROA - openPR.com
Popular Inc Delivers Double Income Stream: New Preferred Stock Dividend Plus Trust Securities Distribution - Stock Titan
Exclusive: Aptar Leadership Team Set for Strategic Updates at Major Investment Conferences - Stock Titan
Medical Properties Trust Dividend Alert: $0.08 Per Share Payable July 17Key Dates Inside - Stock Titan
Exicure Faces Nasdaq Delisting Risk: 60 Days to Submit Compliance Plan for Late Q1 Filing - Stock Titan
Ardent Health Partners Streamlines Brand Identity: What the New Corporate Name Means for Investors - Stock Titan
Chikungunya wins boost Valneva; overall infectious disease stocks fall - BioWorld MedTech
ACXP Stock: Selling Stockholder to Offload Shares with No Procee - GuruFocus
ACXP Stock: Selling Stockholder to Offload Shares with No Proceeds to Company | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling StockholderSEC Filing - marketscreener.com
Q2 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment - MSN
Acurx Pharmaceuticals’ Earnings Call: Progress Amidst Funding Challenges - TipRanks
ACXP: Acurx Pharmaceuticals Receives 'Buy' Rating from HC Wainwr - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock - Investing.com Australia
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 T - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock By Investing.com - Investing.com India
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 Target | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports Improved Q1 2025 Results - TipRanks
Earnings call transcript: Acurx Pharmaceuticals beats Q1 2025 EPS forecast By Investing.com - Investing.com India
Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million - marketscreener.com
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
Acurx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Tesla Stock Is Climbing Monday: What's Going On?Tesla (NASDAQ:TSLA) - Benzinga
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement - TipRanks
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y - Yahoo Finance
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week" - Seeking Alpha
Warren Buffett Announces Historic CEO Transition at Berkshire: Greg Abel to Take Helm in 2026 - Stock Titan
ACXPAcurx Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results - TradingView
Acurx Pharmaceuticals to Reveal Q1 2025 Financial Performance and Key Pipeline Updates - Stock Titan
Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):